Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 3,320 restricted stock units and 3,636 warrants to employees of the Company and the Company's subsidiaries. Each ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed yesterday at $21.35. Confident Inve ...

The updated data showed positive results and supports the company’s aim to start a Phase 111 trial later this year.

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.

Investing.com -- Genmab (NASDAQ: GMAB) has unveiled new data for its cancer drug Rina-S, which is being tested for use in endometrial cancer. This follows promising early results from trials in ...

Genmab (NASDAQ:GMAB) has released new findings regarding its cancer therapy Rina-S, currently under investigation for ...

Genmab A/S (NASDAQ:GMAB) has announced promising new data for its investigational antibody-drug conjugate, rinatabart ...

The company's uterine cancer drug is advancing in its development. Quite a few of them also piled into the American ...